Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Doan's back pain relief superiority claims not supported, FTC judge concludes.

This article was originally published in The Tan Sheet

Executive Summary

NOVARTIS DOAN'S BACK PAIN RELIEF SUPERIORITY CLAIMS NOT SUPPORTED, FTC Administrative Law Judge Lewis Parker said in a March 9 decision and order upholding charges made by the Federal Trade Commission. Novartis is prohibited from claiming Doan's "is more effective than other over-the-counter analgesic drugs for relieving back pain or any other particular kind of pain, unless, at the time of making such representation, respondents possess and rely upon competent and reliable scientific evidence that substantiates the representation," the order states.
Advertisement

Related Content

Doan's FTC Correction Requirement Is "Punitive" And "Irrational" - Novartis
Doan's FTC Correction Requirement Is "Punitive" And "Irrational" - Novartis
Doan's FTC Correction Requirement Is "Punitive" And "Irrational" - Novartis

Topics

Advertisement
UsernamePublicRestriction

Register

PS088214

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel